Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i editorial
15 May 2016

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Back to the future: triglycerides revisitedRead more...

Whether elevated triglycerides represent a causal risk factor has been much debated. However, increasing recent evidence provides a strong case for support. This month’s Landmark article adds to this story.
 
The Bezafibrate Infarction Prevention (BIP) study, a large randomized outcomes study, was designed to assess the efficacy of bezafibrate in preventing cardiovascular events in high risk patients. Results on completion of the trial showed no significant benefit with bezafibrate for the primary outcome (a composite of fatal and nonfatal myocardial infarction plus sudden death).
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
15 May 2016

BIP analysis reaffirms the link between elevated triglycerides and increased mortalityRead more...

The findings from this 22-year follow-up of the BIP study show a direct association between triglyceride levels and all-cause mortality in patients with CHD, with a 26% increase in risk for each 1-unit increase in triglycerides. Importantly, there was a graded increase in risk extending...
focus on...
15 May 2016

Symptomatic polyneuropathy more common with increasing number of metabolic syndrome components Read more...

Polyneuropathy (DSP) is the most common form of diabetic neuropathy and confers substantial morbidity (1). However, as enhanced glucose control has only a marginal impact in reducing the incidence in patients with type 2 diabetes, the relevance of other metabolic factors warrants investigation.
recent publication

Death knell for CETP inhibition? More details on ACCELERATE with evacetrapib Read more...

Treatment with evacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor,...
recent publication

Triglyceride/HDL-C ratio: indicator of risk of sleep apnoea syndromeRead more...

The ratio of serum triglycerides to high-density lipoprotein cholesterol (TG/HDL-C)...
recent publication

HDL characteristics beyond HDL cholesterol concentration: marker or mediator of coronary atherosclerosis? Read more...

Findings from this study in patients with coronary artery disease...
recent publication

Study identifies novel variant for triglyceridesRead more...

In this study, fine gene mapping from 95 lipid genome...
recent publication

Fibroblast growth factor 21: potential for diagnosis of early stage diabetic retinopathy?Read more...

This study suggests that elevated serum fibroblast growth factor 21...
recent publication

Low HDL cholesterol and risk for chronic kidney diseaseRead more...

Low HDL cholesterol has already been shown to be an...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.